ArticleJournal of inflammation (London, England)2025
Baicalein inhibits mycobacterium tuberculosis-induced macrophage M1 polarization depending on the regulation of YY1/RAB10/TLR4 pathway.
Article in Journal of inflammation (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- YY1-activated LINC00926 promotes the survival of mycobacteria and regulates inflammatory response in Mycobacterium tuberculosis-infected macrophages.Archives of microbiology · 2026Article
- Molecular Mechanisms and Therapeutic Potential of Baicalein in Acute Pancreatitis: A Comprehensive Review.Biomolecules · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBaicalein (Bai) has been found to alleviate the progression of tuberculosis (TB) by inhibiting mycobacterium tuberculosis (M.tb)-induced macrophage pyroptosis, so it may be used as an adjuvant treatment for TB. However, the underlying molecular mechanism of Bai remains unclear.
methodsTHP-1 macrophages were infected with M.tb and treated with Bai. The viability and apoptosis of macrophages were examined with CCK8 assay, flow cytometry and TUNEL staining. The levels of inflammatory cytokines were tested by ELISA. Macrophage M1 polarization was assessed by detecting CD86
resultsM.tb promoted macrophage M1 polarization, apoptosis and inflammation, while this effect was abolished by Bai treatment. Bai decreased RAB10 expression, and RAB10 overexpression reversed the anti-TB effect of Bai. YY1 enhanced the transcription of RAB10, and YY1 knockdown inhibited M.tb-induced macrophage M1 polarization by reducing RAB10 expression. Also, Bai could decrease YY1 expression, and YY1 overexpression eliminated the regulation of Bai on M.tb-induced macrophage M1 polarization. Moreover, RAB10 could interact with TLR4 to activate TLR4/MYD88/NF-κB pathway, thus promoting M.tb-induced macrophage M1 polarization.
conclusionBai might play anti-TB effect by regulating YY1/RAB10/TLR4/MYD88/NF-κB pathway, providing a novel idea for the treatment of TB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.